DAPAGLYN 10 TAB

About

DAPAGLYN 10 TAB contains Dapagliflozin 10mg, which is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This class of medication is primarily used in the management of type 2 diabetes mellitus. Dapagliflozin works by blocking the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose from the filtered blood back into the bloodstream. By inhibiting SGLT2, Dapagliflozin causes the kidneys to excrete more glucose in the urine, thereby lowering blood glucose levels independently of insulin.

Beyond its glucose-lowering effects, Dapagliflozin has demonstrated significant cardiovascular and renal benefits. It has been shown to reduce the risk of cardiovascular death, hospitalization for heart failure, and the progression of chronic kidney disease in patients with type 2 diabetes, and also in patients with heart failure or CKD without diabetes. Its mechanism also leads to modest weight loss and blood pressure reduction, making it a valuable therapeutic option for comprehensive management of type 2 diabetes and its associated complications.

Uses

• Treatment of type 2 diabetes mellitus.
• Reduces the risk of cardiovascular death and heart failure hospitalization.
• Slows the progression of chronic kidney disease.
• Management of chronic heart failure with reduced ejection fraction.

Directions For Use

Take orally, once daily, in the morning, with or without food, as prescribed by your physician.

Benefits

• Effectively lowers blood glucose levels.
• Promotes modest weight loss.
• Reduces blood pressure.
• Decreases the risk of major adverse cardiovascular events.
• Slows the progression of kidney disease.
• Reduces the risk of hospitalization for heart failure.

Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination (polyuria)
• Increased thirst
• Dizziness
• Hypotension (low blood pressure)
• Diabetic ketoacidosis (rare)
• Acute kidney injury (rare)
• Fournier's gangrene (very rare)
• Dehydration
• Back pain
• Nausea

Safety Measures

• Alcohol - Excessive alcohol consumption can increase the risk of diabetic ketoacidosis and hypoglycemia when taking Dapagliflozin.
• Pregnancy - Not recommended, especially during the second and third trimesters, due to potential adverse effects on fetal kidney development.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if Dapagliflozin is excreted in human milk and could harm the infant.
• Liver - Use with caution in patients with severe liver impairment.
• Kidney - Not recommended for patients with an eGFR persistently below 25 mL/min/1.73 m². Monitor kidney function regularly.
• Lung - No direct significant impact on lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.